Profile: Athenex Inc (ATNX.OQ)
17 Oct 2019
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company's business includes medical technology centers and a manufacturing supply chain across both China and North America. The Company has approximately 10 products under development throughout the world with multiple offices in China and the United States.
The Company's delivery system (P-glycoprotein (P-gp) pump inhibitor), is a technology platform, which enables oral absorption of a range of anticancer drugs and are given intravenously due to poor oral absorption. It offers Oraxol, an oral formulation of paclitaxel used for the treatment of breast, lung, ovarian and pancreatic cancer. It also offers Orateacan, an oral formulation of Irinotecan, which is delivered intravenously to treat colorectal cancer. The Company's Oradoxel is an oral formulation of Docetaxel, which is used to treat head and neck, gastric, breast, prostate and non-small cell lung cancers. It also offers an oral formulation of Topotecan, which is used for the treatment of lung, ovarian, leukemia cancers.
The Company's Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's KX01 ointment formulation is used for the treatment of actinic keratosis. The KX01 is an orally active and highly selective inhibitor of Src tyrosine kinase signaling and tubulin polymerization. The Company's KX01 promotes the induction of p53, G2/M arrest of proliferating cell populations and subsequent apoptosis through the stimulation of Caspase-3 and Poly (ADP-ribose) polymerase (PARP) cleavage. The Company's KX02 is an orally active inhibitor against a panel of central nervous system tumor cell lines, including glioblastoma multiforme (GBM). The Company's KX02 is also effective against GBM tumor cells that are resistant to Temozolomide (T98G). The Company is also developing a range of oncology symptom therapies for addressing issues, such as chemotherapy induced nausea and radiation skin burns. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of irradiation-induced dermatitis, and intranasal Granisetron, which is used for the treatment of chemotherapy-induced nausea/vomiting. The MJ Antipruritic Hydrogel is used to treat scar-related intractable pruritus.
1001 Main St Ste 600
BUFFALO NY 14203-1009